This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.
The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Gerald Scott Winder, MD, MSc
Consultant relationship with GSK; Has not ended; Consultant relationship with Novo Nordisk; Has not ended
Reem Sharaiha, MD, MSc
research support relationship with boston scientific; Has not ended; Consultant relationship with Surgical Intuitive; Has ended
Jonny Sexton, PhD
Grant/Research Support relationship with Bristol Myers Squibb; Has not ended
Terry Cheuk-Fung Yip, PhD
Grant/Research Support relationship with Gilead Sciences; Has not ended; Speaking and Teaching relationship with Gilead Sciences; Has not ended; Consultant relationship with Gilead Sciences; Has not ended
Matthew Akiyama, MD, MSc
Grant/Research Support relationship with AbbVie; Has ended; Grant/Research Support relationship with Gilead Sciences; Has not ended
Norah Terrault, MD, MPH, FAASLD
Grant/Research Support relationship with Durect Corp; Has not ended; Grant/Research Support relationship with ImmunoCore; Has not ended; Grant/Research Support relationship with Helio Health; Has not ended; Grant/Research Support relationship with Eiger Pharmaceuticals; Has not ended; Grant/Research Support relationship with GSK; Has not ended; Royalties or patent beneficiary relationship with Elseiver; Has not ended; Board member relationship with HBV Foundation; Has not ended; Executive role relationship with AASLD; Has not ended; Grant/Research Support relationship with Genentech-Roche; Has not ended; Executive role relationship with Hepatitis B Foundation; Has not ended
Juan Pablo Arab, MD, FRCPC
No Relevant Financial Relationships
Philip Newsome, MD, PhD
None
Meena Bansal, MD, FAASLD
Advisor relationship with Boston Pharma; Has not ended; Advisor relationship with Boeheringer-Ingelheim; Has not ended; Advisor relationship with The Kinetix Group; Has not ended; Advisor relationship with Merck; Has not ended; Advisor relationship with GSK; Has not ended; Advisor relationship with NOVO Nordisk; Has not ended; Advisor relationship with Fibronostics; Has not ended; Advisor relationship with Madrigal; Has not ended
Frank DiPaola, MD
Consultant relationship with Mirum Pharmaceuticals; Has not ended
Anahita Rabiee, MD
Investigator-initiated studies (IIS) relationship with Grifols; Has not ended
Lily Dara, MD
Consultant relationship with Kezar Pharmaceuticals; Has ended; Consultant relationship with Intercept Pharmaceuticals; Has ended; Grant/Research Support relationship with Intercept Pharmaceuticals; Has not ended; Consultant relationship with Agios; Has not ended
James Luyendyk, PhD
No Relevant Financial Relationships
Jay Hoofnagle, MD, FAASLD
No Relevant Financial Relationships
Ehiamen Okoruwa, MD
Marlyn Mayo, MD, FAASLD
Grant/Research Support relationship with Gilead; Has not ended; Consultant relationship with Kezar; Has ended; Consultant relationship with Ironwood; Has ended; Consultant relationship with Mirum; Has not ended; Consultant relationship with Intercept; Has not ended; Consultant relationship with Gilead; Has not ended; Grant/Research Support relationship with Mirum; Has not ended; Consultant relationship with GSK; Has ended; Grant/Research Support relationship with CymaBay; Has ended; Consultant relationship with CymaBay; Has ended; Grant/Research Support relationship with GSK; Has not ended; Grant/Research Support relationship with Intercept; Has ended; Consultant relationship with IntraSana; Has ended; Grant/Research Support relationship with Ipsen; Has not ended; Consultant relationship with Ipsen; Has not ende
Amy Taylor, MD
No Relevant Financial Relationships
David Kleiner, MD, PhD
No Relevant Financial Relationships
Mark Avigan, MD, CM, FAASLD
No Relevant Financial Relationships
Melissa Palmer, MD, FAASLD
No Relevant Financial Relationships